Biomatter closed an oversubscribed Series A to raise $18 million, aiming to scale its design-and-deliver enzyme business built around AI-designed reaction outcomes. The company says its enzyme programs are already embedded in commercial products, including Thermo Fisher Scientific’s Invitrogen SuperScript V Reverse Transcriptase, and a program engineered for mRNA vaccine manufacturing designed to function without SAM. Biomatter also reported building a pipeline with 25+ enterprise customers and 50+ enzymes delivered. The new facility plan is a 2,000-square-meter design-and-testing site in Vilnius expected to open in 2027, with the stated goal of compressing development cycles from weeks to days—an execution lever for industrial biotech and biomanufacturing partners.